EUCTR2019-002126-75-Outside-EU/EEA进行中（未招募）1 期
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Sequential, Ascending, Multidose Study to Evaluate the Safety and Efficacy of Linaclotide in Pediatric Participants (Age 2 to 5 Years) with Functional Constipation
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Allergan
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Participant weighs = 10 kg at the time the parent/guardian/legally authorized representative (LAR) has provided signed consent
- •Participant meets modified Rome III criteria for FC: For at least 2 months before Screening (Visit 1) (for participants aged = 4 years old), or for at least 1 month before Screening (Visit 1) (for participants aged < 4 years old), the participant has had 2 or fewer defecations (with each defecation occurring in the absence of any laxative, suppository, or enema use during the preceding 24 hours) per week.
- •In addition, at least once per week, participant must meet 1 or more of the following:
- •-History of retentive posturing or excessive volitional stool retention
- •-History of painful or hard bowel movements (BMs)
- •-Presence of a large fecal mass in the rectum
- •-History of large diameter stools that may obstruct the toilet
- •At least one episode of fecal incontinence per week after the acquisition of toileting skills
- •-Participant is willing to discontinue any laxatives used before the Preintervention Visit in favor of the protocol- permitted rescue medicine
- •-Parent/guardian/LAR and caregiver must provide written informed consent before the initiation of any study-specific procedures
- •-Caregiver who will be completing the eDiary is able to read and/or understand the assessments in the eDiary device and must undergo training
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 35
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •For participants aged = 4 years old: Participant meets Rome III criteria for Child/Adolescent IBS: At least once per week for at least 2 months before Screening (Visit 1), the participant has experienced abdominal discomfort (an uncomfortable sensation not described as pain) or pain associated with 2 or more of the following at least 25% of the time:
- •-Improvement with defecation
- •-Onset associated with a change in frequency of stool
- •-Onset associated with a change in form (appearance) of stool
- •Participant has required manual dis-impaction any time prior to randomization or dis-impaction during in-patient hospitalization within 1 year prior to randomization
- •Participant currently has both unexplained and clinically significant alarm symptoms (lower GI bleeding [rectal bleeding or heme-positive stool], iron-deficiency anemia, or any unexplained anemia, or weight loss) and systemic signs of infection or colitis, or any neoplastic process
- •Participant has had surgery that meets any of the following criteria:
- •-Surgery to remove a segment of the GI tract at any time before Screening (Visit 1)
- •-Surgery of the abdomen, pelvis, or retroperitoneal structures during the 6 months before the Screening Visit
- •-An appendectomy or cholecystectomy during the 60 days before Screening (Visit 1)
- •-Other major surgery during the 30 days before Screening (Visit 1)
- •Participant has a mechanical bowel obstruction or pseudo-obstruction.
- •Participant has a known allergy or sensitivity to the study intervention or its components or other medications in the same drug class
- •Participant has any of the following conditions:
- •-Celiac disease, or positive serological test for celiac disease or the condition is suspected but has not been ruled out by endoscopic biopsy
- •-Cystic fibrosis
- •-Hypothyroidism that is untreated or treated with thyroid hormone at a dose that has not been stable for at least 3 months prior to Screening (Visit 1)
- •-Down's syndrome or any other chromosomal disorder
- •-Active anal fissure (ie, participant reports having streaks of blood on the stool or on toilet paper and/or pain/crying with bowel movement within 2 weeks prior to Screening). (Note: Anal fissures that have resolved at least 2 weeks prior to screening would not be exclusionary.) However, if in the investigator's opinion, an anal fissure(s) may be the primary cause of participant's modified Rome III FC criteria, the participant would not be eligible to participate in the study.
- •-Anatomic malformations (eg, imperforate anus, anal stenosis, anterior displaced anus)
- •-Intestinal nerve or muscle disorders (eg, Hirschprung disease, visceral myopathies, visceral neuropathies)
- •-Neuropathic conditions (eg, spinal cord abnormalities, neurofibromatosis, tethered cord, spinal cord trauma)
- •-Lead toxicity, hypercalcemia
- •-Neurodevelopmental disabilities (early-onset, chronic disorders that share the essential feature of a predominant disturbance in the acquisition of cognitive, motor, language, or social skills, which has a significant and continuing impact on the developmental progress of an individual) producing a cognitive delay that precludes comprehension and completion of the daily eDiary or other study-related questionnaires (Note: Participants are excluded if the person who will be completing the daily eDiary or other study-related questionnaires meets this criterion.)
- •-Inflammatory bowel disease
- •-Childhood functional abdominal pain syndrome
- •-Childhood functional abdominal pain
- •-Poorly treated or p
研究者
相似试验
进行中（未招募）
1 期
Clinical Study of Inhaled GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)Pulmonary Arterial Hypertension (PAH)MedDRA version: 20.0Level: LLTClassification code 10077739Term: Pulmonary arterial hypertension WHO functional class ISystem Organ Class: 100000004855EUCTR2019-002669-37-ATGB002, Inc.80
进行中（未招募）
1 期
A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection FractioHeart failure (HF) with reduced ejection fraction (HFrEF)MedDRA version: 26.1Level: LLTClassification code: 10078289Term: Heart failure with reduced ejection fraction Class: 10007541CTIS2023-508736-62-00Cardurion Pharmaceuticals Inc.400
进行中（未招募）
1 期
This is a Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid TreatmentSubjects with Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid TreatmentMedDRA version: 21.0Level: PTClassification code 10036099Term: Polymyalgia rheumaticaSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2021-000648-23-DEAbbVie Deutschland GmbH & Co. KG160
招募中
1 期
Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitislcerative ColitisMedDRA version: 20.1Level: LLTClassification code: 10045365Term: Ulcerative colitis Class: 10017947CTIS2023-508679-34-00Anaptysbio Inc.147
进行中（未招募）
1 期
This is a Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid TreatmentSubjects with Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid TreatmentMedDRA version: 21.0Level: PTClassification code 10036099Term: Polymyalgia rheumaticaSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2021-000648-23-ITABBVIE DEUTSCHLAND GMBH & CO. KG200